ARTICLE | Company News
Aronex other research news
October 9, 1995 7:00 AM UTC
The company received two Phase I SBIR grants totaling $200,000 from the National Institute of Allergy and Infectious Diseases for the preclinical development of its CMV therapeutic, AR132. One grant w...